Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

T. Vesikari; J. Kirstein; G. Devota Go; B. Leav; M.E. Ruzycky; L. Isakov; M. de Bruijn; J. Oberye; E. Heijnen

doi:10.1016/S2213-2600(18)30108-5

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

T. Vesikari
, J. Kirstein
, G. Devota Go
, B. Leav
, M.E. Ruzycky
, L. Isakov
, M. de Bruijn
, J. Oberye
, E. Heijnen

Research output: Contribution to journal › Article › Scientific › peer-review

63 Citations (Scopus)

Original language	English
Pages (from-to)	345-356
Journal	The Lancet Respiratory Medicine
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/S2213-2600(18)30108-5
Publication status	Published - 2018
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publication forum classification

Publication forum level 1

Access to Document

10.1016/S2213-2600(18)30108-5

Cite this

Vesikari, T., Kirstein, J., Devota Go, G., Leav, B., Ruzycky, M. E., Isakov, L., de Bruijn, M., Oberye, J., & Heijnen, E. (2018). Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. The Lancet Respiratory Medicine, 6(5), 345-356. https://doi.org/10.1016/S2213-2600(18)30108-5

@article{72106b8be6734e819cfbbf3e37e939ee,

title = "Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial",

author = "T. Vesikari and J. Kirstein and \{Devota Go\}, G. and B. Leav and M.E. Ruzycky and L. Isakov and \{de Bruijn\}, M. and J. Oberye and E. Heijnen",

year = "2018",

doi = "10.1016/S2213-2600(18)30108-5",

language = "English",

volume = "6",

pages = "345--356",

number = "5",

}

Vesikari, T, Kirstein, J, Devota Go, G, Leav, B, Ruzycky, ME, Isakov, L, de Bruijn, M, Oberye, J & Heijnen, E 2018, 'Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial', The Lancet Respiratory Medicine, vol. 6, no. 5, pp. 345-356. https://doi.org/10.1016/S2213-2600(18)30108-5

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. / Vesikari, T.; Kirstein, J.; Devota Go, G. et al.
In: The Lancet Respiratory Medicine, Vol. 6, No. 5, 2018, p. 345-356.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

AU - Vesikari, T.

AU - Kirstein, J.

AU - Devota Go, G.

AU - Leav, B.

AU - Ruzycky, M.E.

AU - Isakov, L.

AU - de Bruijn, M.

AU - Oberye, J.

AU - Heijnen, E.

PY - 2018

Y1 - 2018

U2 - 10.1016/S2213-2600(18)30108-5

DO - 10.1016/S2213-2600(18)30108-5

M3 - Article

SN - 2213-2600

VL - 6

SP - 345

EP - 356

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 5

ER -

Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L et al. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. The Lancet Respiratory Medicine. 2018;6(5):345-356. doi: 10.1016/S2213-2600(18)30108-5